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Abstract
Purpose BRCA2 mutation carriers are offered annual breast screening with MRI and mammography. The aim of this study 
was to investigate the supplemental value of mammographic screening over MRI screening alone.
Methods In this multicenter study, proven BRCA2 mutation carriers, who developed breast cancer during screening using 
both digital mammography and state-of-art breast MRI, were identified. Clinical data were reviewed to classify cases in 
screen-detected and interval cancers. Imaging was reviewed to assess the diagnostic value of mammography and MRI, using 
the Breast Imaging and Data System (BI-RADS) classification allocated at the time of diagnosis.
Results From January 2003 till March 2019, 62 invasive breast cancers and 23 ductal carcinomas in situ were diagnosed 
in 83 BRCA2 mutation carriers under surveillance. Overall screening sensitivity was 95.2% (81/85). Four interval cancers 
occurred (4.7% (4/85)). MRI detected 73 of 85 breast cancers (sensitivity 85.8%) and 42 mammography (sensitivity 49.9%) 
(p < 0.001).
Eight mammography-only lesions occurred. In 1 of 17 women younger than 40 years, a 6-mm grade 3 DCIS, retrospectively 
visible on MRI, was detected with mammography only in a 38-year-old woman. The other 7 mammography-only breast 
cancers were diagnosed in women aged 50 years and older, increasing sensitivity in this subgroup from 79.5% (35/44) to 
95.5% (42/44) (p ≤ 0.001).
Conclusions In BRCA2 mutation carriers younger than 40 years, the benefit of mammographic screening over MRI was very 
small. In carriers of 50 years and older, mammographic screening contributed significantly. Hence, we propose to postpone 
mammographic screening in BRCA2 mutation carriers to at least age 40.
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Abbreviations
BI-RADS  Breast Imaging Reporting and 
Data System
DCIS  Ductal carcinoma in situ
HER2  Human epidermal growth fac-
tor receptor 2
ILC  Invasive lobular carcinoma
Invasive carcinoma NST  Invasive carcinoma no special 
type
HEBON  Hereditary Breast and Ovar-
ian Cancer Research Group 
Netherlands
MRI  Magnetic Resonance Imaging
Introduction
Women with a BRCA1 or BRCA2 mutation have a strongly 
elevated risk of developing breast cancer [1]. Therefore, 
annual screening with MRI and mammography starting at 
young age is advised for women who do not opt for bilateral 
prophylactic mastectomy, though the optimal screening regi-
men is not set yet.
In women with a high familial or genetic risk, breast MRI 
was originally introduced as an adjunct to mammographic 
screening. However, increasing breast MR expertise and 
technologic advances over the years have made that breast 
MR nowadays outperforms mammography in the early 
detection of invasive breast cancer as well as in the detection 
of ductal carcinoma in situ (DCIS) [2]. Recent studies dem-
onstrate that, especially in BRCA1 mutation carriers under 
the age of 40, there is little benefit of mammographic screen-
ing when MRI screening is also performed [3–5]. Further-
more, the exposure to low-dose ionizing radiation as from 
annual mammographic screening might be more harmful in 
BRCA mutation carriers. The BRCA gene is involved in the 
pathway of repair of DNA double strand breaks. In BRCA 
gene mutation carriers, the impaired function of this path-
way may lead to a higher risk of radiation-induced breast 
cancer [6–8].
As a consequence, in 2018, the Dutch screening guide-
lines were modified for BRCA1 mutation carriers, nowadays 
starting with supplemental biennial mammography only 
from the age of 40 [9].
From the point of breast cancer risk and radiation sensi-
tivity, it would be reasonable to screen BRCA1 and BRCA2 
mutation carriers according to the same protocol. However, 
characteristics of cancers detected in BRCA2 carriers dif-
fer significantly from those detected in BRCA1 carriers. 
While BRCA1 carriers predominantly present with high-
grade hormone receptor-negative invasive breast cancer, 
BRCA2 mutation carriers have more luminal breast cancers 
and a higher proportion of DCIS, sometimes only detected 
as mammographic calcifications [10–12]. Consequently, in 
BRCA2 carriers, supplemental annual mammography from 
the age of 30 is still regarded as the standard of care.
The aim of this study was to assess whether this bi-modal 
screening protocol (i.e., with digital mammography from age 
30 and state-of-art MRI) is still appropriate in BRCA2 muta-
tion carriers. For this, we evaluated the mode of detection 
in BRCA2 mutation carriers who developed breast cancer 
while under surveillance.
Patients and methods
Patients
In this retrospective study, we included women with a proven 
BRCA2 mutation who developed breast cancer during sur-
veillance with digital mammography and breast MRI in one 
of the five participating Dutch university hospitals (Erasmus 
University Medical Center Rotterdam, Radboud University 
Medical Center Nijmegen, Maastricht University Medical 
Center, University Medical Center Leiden, and University 
Medical Center Groningen) or in the Netherlands Cancer 
Institute in Amsterdam. We included consecutive series 
of BRCA2 breast cancer cases provided by the databases 
of the family breast cancer clinics of Erasmus University 
Medical Center Rotterdam and Radboud University Medical 
Center Nijmegen. For the other centers, we included BRCA2 
breast cancer cases provided by the collaborative group on 
Hereditary Breast and Ovarian Cancer in The Netherlands 
(HEBON) [13].
Inclusion started after introduction of digital mammogra-
phy which was between January 2003 (Radboud University 
Medical Center Nijmegen) and September 2006 (Erasmus 
University Medical Center Rotterdam). The inclusion period 
ended in March 30, 2019.
All BRCA2 breast cancer patients provided written 
informed consent.
Women in whom a BRCA2 mutation was determined 
after breast cancer diagnosis and BRCA2 mutation carriers 
with breast cancer detected in specimen from prophylac-
tic mastectomy were excluded from the analysis. We also 
excluded women in whom only one of the screening meth-
ods was used.
Women with a prior history of breast cancer were 
included.
Methods
Age
We divided the women in two age groups: women diagnosed 
with breast cancer before age 40 and women diagnosed with 
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breast cancer at age 40 and older. We chose this age limit for 
two reasons. Firstly, previous research in women at increased 
risk showed a very low added value of mammography in the 
screening of women under 40 years of age, albeit series were 
too small to provide specific information for women with 
BRCA2 mutations. Secondly, the breast cancer risk from 
low-dose ionizing radiation as from annual mammographic 
screening is strongly dependent on age at exposure with 
higher risks at younger ages [5, 14, 15].
Breast MRI
According to the Dutch guidelines [9], women with a proven 
BRCA2 mutation were offered annual breast MRI screening 
from age 25 till age 60 and annual mammographic screening 
starting at age 30. After age 60, breast cancer screening is 
continued with annual mammography, or, in case of dense 
breast tissue, with annual screening alternating mammog-
raphy and MRI.
Breast MRI was performed in each center using local pro-
tocols that all met the requirements of currently accepted 
international guidelines [16], including at least three high-
resolution T1-weighted acquisitions obtained before, early 
(90s), and late after (5–7 min) contrast administration. 
Dedicated analysis software (allowing for the creation of 
maximum intensity projections, signal intensity versus time 
curves, and color-coded overlays of enhancement patterns) 
and MR-guided biopsy tools were available in all centers. All 
centers had extensive experience with screening of women 
with familial or genetic predisposition for breast cancer.
Data collection
The images and related reports of all patients at the time 
of diagnosis were reviewed by one or two of the dedicated 
breast radiologists (IMO, RM, CL, ML, NV) in order to 
assess whether the breast cancers were screen-detected or 
interval cancers and whether the cancers were visible on 
mammography and MRI. One radiologist (IMO) reviewed 
nearly all cases. The mammograms and breast MRI exami-
nations were reported at the time of diagnosis according to 
the Breast Imaging Reporting and Data System (BI-RADS) 
[17]. The BI-RADS classifications (both for mammography 
and MRI) allocated at the time of diagnosis were used for 
this evaluation. BI-RADS classifications 0, 3, 4, and 5 were 
defined as positive findings because additional work-up was 
indicated.
A screen-detected breast cancer was defined as a breast 
cancer found during a screening round by breast MRI and/
or mammography. If a breast cancer was identified clinically 
(became palpable or caused other symptoms) in between 
two screening rounds, it was considered an interval cancer.
The pathology reports were evaluated for tumor char-
acteristics. In women who underwent primary surgical 
treatment, the largest diameter of the tumor as mentioned 
in the pathology report was recorded to indicate size. In 
case of multifocal or multicentric disease, the size of the 
largest cancer was registered. In patients treated with neo-
adjuvant chemotherapy, the largest diameter measured on the 
pre-therapeutic MRI was recorded as the size of the breast 
cancer.
Statistical analysis
Sensitivity for both screening modalities (breast MRI and 
mammography) was assessed separately. For the comparison 
of the screening modalities, we used the data of patients for 
whom results were available for both modalities at the time 
of diagnosis. The differences in sensitivity between the two 
were tested by a McNemar’s test for paired proportions.
We also compared sensitivity for breast MRI and mam-
mography separately for the two age groups defined above 
(women diagnosed before age 40 and women diagnosed 
at age 40 years and older). The differences in sensitivity 
between age groups were tested using Fisher’s exact test.
A two-sided p value of lower than 0.05 was regarded as 
statistically significant. Statistical analyses were performed 
using STATA (STATA version 15.1).
Results
From January 2003 to March 2019, 83 BRCA2 mutation 
carriers were diagnosed with 85 breast cancers while under 
surveillance with both MRI and digital mammography. In 
the majority of cases (in 75 of 85 cases), MRI and mam-
mography were performed simultaneously or within a short 
period of time. One woman presented with a synchronous 
contralateral breast cancer, another woman had a metachro-
nous contralateral breast cancer. Mean age at diagnosis was 
49.3 years (range 27–70); 17 breast cancers were diagnosed 
before age 40 (20.0%).
Sixty-two invasive breast cancers with a mean size of 
10.1  mm (range 3–27  mm) and 23 DCIS lesions were 
detected. Tumor characteristics can be found in Table 1. 
The majority, 68.2% (58/85) of breast cancers, was detected 
in an early stage (DCIS or invasive breast cancer ≤ 10 mm). 
Lymph node status was determined to be positive in 12 of 
61 women in whom at least a sentinel lymph node biopsy 
was performed (19.7%).
Overall, 81 out of 85 breast cancers were screen-
detected, resulting in an overall screening sensitivity 
of 95.2% (81/85). Four interval cancers occurred (4.7% 
(4/85)) in women aged 39, 42, 50, and 51 years with sizes 
of, respectively, 15, 12, 17, and 19 mm. Based upon the 
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re-evaluation of the imaging examinations, two of them 
were retrospectively visible on MRI. Three of 4 interval 
cancers were grade 3 triple-negative breast cancer.
MRI detected 73 of 85 breast cancers (sensitivity 
85.8%) and mammography 42 (sensitivity 49.9%) (p 
value < 0.001). For invasive breast cancer, MRI per-
formed significantly better than mammography (sensi-
tivity, respectively, 90.3% (56/62) versus 43.5% (27/62), 
(p < 0.001)). For the detection of DCIS, the difference was 
not statistically significant (sensitivity, respectively, 73.9% 
(17/23) and 65.2% (15/23) (p = 0.791)).
The screening sensitivity of the combination of imaging 
modalities, and the screening sensitivity of breast MRI 
and mammography separately, was also determined for 
the pre-defined age groups (Table 2).
Thirty-nine breast cancers were detected by MRI only 
(45.8% (39/85)) and 8 by mammography only (9.4% (8/85) 
(Table 3)). It should be noted that only two of the cancers 
detected with mammography only were invasive. One of 
the mammography-only breast cancers was diagnosed 
before age 40. It concerned a 6 mm DCIS grade 3 in a 
38-year-old woman, retrospectively also visible on MRI.
The other 7 mammography-only breast cancers were 
diagnosed in women aged 50 years and older (Table 3 and 
Fig. 1). This subgroup consisted of 42 women with 44 breast 
cancers of which 35 were correctly depicted by MRI (sensi-
tivity 79.5% (35/42)). Decombination of MRI and mammog-
raphy increased the screening sensitivity in this subgroup to 
95.5% (42/44).
No mammography-only breast cancers occurred in 
the subgroup of 24 women diagnosed with breast cancer 
between age 40 and 49 (Fig. 1).
Discussion
In this multicenter study, the screening results in BRCA2 
mutation carriers showed a high screening sensitivity of 
95.2% as well as a high percentage of early-stage breast 
cancer (68.2%) and a very low fraction of interval cancers 
(4.7%). As expected, the sensitivity of MRI (85.8%) was 
significantly higher than the sensitivity of mammographic 
screening (49.9%) (p value < 0.001). The most impor-
tant finding of the current study is that in the 17 BRCA2 
Table 1  Tumor characteristics 
of 85 breast cancers
DCIS ductal carcinoma in situ, HER2 human epidermal growth factor receptor 2
*Her2 status not available in 3 patients
**Including 4 cases with micrometastases
*** Nodal status unknown in one patient with invasive breast cancer
Histologic type Number
DCIS n = 23 (27.1%) Histological grade DCIS
Grade 1 0
Grade 2 12
Grade 3 11
Invasive breast cancer n = 62 (72.9%)
(Invasive breast cancer with DCIS component n = 25)
Histology-invasive breast cancer
Invasive breast cancer no special type 54
Invasive lobular carcinoma 6
Other 2
Histological grade invasive breast cancer
Bloom and Richardson Grade 1 7
Bloom and Richardson Grade 2 30
Bloom and Richardson Grade 3 25
Size invasive breast cancer
 ≤ 10 mm 35 (56.5%)
 > 10 ≤ 20 mm 25 (40.3%)
 > 20 mm 2 (3.2%)
Receptor status invasive breast cancer 
n = 59*
ER+ and/or PR+, HER2− 42 (71.2%)
ER+, PR+, HER2+ 3 (5.1%)
ER−, PR−, HER2+ 3 (5.1%)
ER+, PR_, HER2+ 1 (1.7%)
Triple− 10 (16.9%)
Nodal status
n = 61***
N+ 19.7%** (12/61)
N− 80.3% (49/61)
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mutation carriers diagnosed with breast cancer before age 
40, there was just one mammography-only lesion concern-
ing a 6 mm DCIS grade 3 in a 38-year-old woman (5,9% 
(1/17)). This lesion was retrospectively visible on MRI and 
therefore not truly MRI occult. The additional value of mam-
mography is negligibly small in BRCA2 carriers younger 
than 40 years old.
However, in BRCA2 mutation carriers, aged 50 and older 
mammographic screening did demonstrate a screening bene-
fit in addition to MR screening. Of the 44 cancers diagnosed 
above age 50, 7 cancers, concerning predominantly DCIS 
but also small invasive lesions with an extensive intraductal 
component, were detected by mammography only, increas-
ing sensitivity in this subgroup from 79.5% (35/44) to 95.5% 
Table 2  Screening sensitivity according to screening modality and age at diagnosis
Sensitivity All breast cancers n = 85 Breast cancers diagnosed 
before age 40
N = 17 (20.0%)
Breast cancers diagnosed at 
age ≥ 40 years
n = 68 (80.0%)
p
Combined screening
All breast cancers 95.2% (81/85) 94.1% (16/17) 95.6% (65/68) 1.000
DCIS 100% (23/23) 100% (6/6) 100% (17/17) 1.000
Invasive breast cancer 93.5% (58/62) 90.1% (10/11) 94.1% (48/51) 1.000
MR screening
All breast cancers 85.8% (73/85) 88.2% (15/17) 85.3% (58/68) 1.000
DCIS 73.9% (17/23) 83.3% (5/6) 70.6% (12/17) 1.000
Invasive breast cancer 90.3% (56/62) 90,9% (10/11) 90.1% (46/51) 1.000
X screening
All breast cancers 49,4% (42/85) 47.1% (8/17) 50.0% (34/68) 1.000
DCIS 65.2% (15/23) 50.0% (3/6) 70.6% (12/17) 0.621
Invasive breast cancer 43.5% (27/62) 45.4% (5/11) 43.1% (22/51) 1.000
Table 3  Mammography-only detected breast cancers
NST no special type, EIC extensive intraductal component, np sentinel node or axillary lymph node dissection not performed
*In retrospect visible on MRI
No Age at diagnosis Tumor type Grade Size Nodal status
1 57 Invasive breast 
cancer NST with 
EIC *
ER-, PR-, Her2-
2 5 mm N-
2 54 DCIS 3 10 mm np
3 54 Invasive breast 
cancer NST with 
EIC
ER+, PR+, Her2−
3 3 mm N-
4 57 DCIS 2 6 mm np
5 51 DCIS 2 20 mm np
6 38 DCIS* 3 6 mm np
7 57 DCIS 3 15 mm np
8 59 DCIS* 2 14 mm np
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Fig. 1  All breast cancer cases and mammography-only breast cancer 
cases per 10-year age group
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(42/44) (p = 0.0082), indicating that mammography may 
have supplemental value in this age group.
Strikingly, mammographic screening did not contribute 
over MRI screening in women diagnose between age 40 
and 49 years. The very limited additional value of mam-
mographic screening combined with the increased radiation 
risks in young mutation carriers [5, 6] and the additional 
burden placed upon patients by supplemental mammogra-
phy are arguments to postpone the start of mammographic 
screening to at least age 40. The lack of screening benefit of 
mammography over MRI in women between 40 and 49 years 
of age suggests that mammographic screening might even 
be postponed to age 50. A prerequisite is that annual MRI 
screening is performed in a dedicated center.
One could argue that the DCIS cases depicted by mam-
mography-only represent overdiagnosis. However, an argu-
ment against overdiagnosis is that all DCIS lesions detected 
with mammography-only as well as with MRI were grade 
2 or grade 3, which seems relevant in this high-risk popula-
tion. Moreover, it is known that pre-invasive lesions, such as 
DCIS, are common in BRCA-associated breast cancers [18] 
and that in high-risk women with DCIS, the prevalence of a 
BRCA1/2 mutation is high [19]. Yang and colleagues [20] 
found, in BRCA-associated breast cancers with an invasive 
and an in situ component, a high concordance of DCIS and 
invasive phenotypes. These findings may suggest that DCIS, 
like in sporadic breast cancer, may be considered as a step in 
the pre-invasive progression pathways in BRCA mutation-
related breast cancers.
Phi et al. [3] conducted a meta-analysis of six high-risk 
prospective screening studies and reported on 72 BRCA2 
breast cancer cases. In contrast to our results, one-third 
(6/18) of breast cancers diagnosed before age 40 years were 
detected with mammography only. However, in this meta-
analysis, the MRI sensitivity was just 50% (9/18) for the 
younger age group and 73.6% (53/72) for all ages. The poor 
MRI screening results of this meta-analysis can likely be 
explained by the fact that some of the included studies were 
multicenter studies starting with breast MRI screening at the 
beginning of the MRI-era and, therefore, were conducted in 
centers with little MRI screening experience. MR screening 
performance has clearly improved since then [2, 4, 21, 22].
The prospective cohort study of the High Risk Ontario 
Breast Screening Program [23] included, from July 2011 to 
December 2016, 8782 high-risk women, of which 1885 were 
BRCA1/2 mutation carriers. In mutation carriers, younger 
than 40 years of age the sensitivity of MRI alone was compa-
rable to the combination of MRI and mammography (96.8% 
vs 100%, p 0.99). In carriers aged 50–69 years, combining 
MRI and mammography increased sensitivity compared 
with MRI alone (92.7% vs 83.5%, p 0.02), which seems in 
line with our findings. However, outcomes were not given 
for BRCA1 and BRCA2 mutation carriers separately.
Other studies [12, 24–30] presenting screening results in 
proven BRCA2 mutation carriers had small numbers, varying 
between 2 and 25 breast cancer cases. The mammographic 
benefit in these studies was limited, especially in women diag-
nosed with breast cancer before age 40. However, the small 
numbers make it difficult to draw solid conclusions.
Krammer [31] presented the results of 496 BRCA breast 
cancer cases diagnosed between 1999 and 2013. None of the 
211 BRCA2 breast cancers were identified by mammography 
only. However, at the time of breast cancer diagnosis, nearly 
half of the participants had clinical symptoms. Therefore, 
the outcomes are difficult to compare with ours and that of 
the above-mentioned studies, but underline the observation 
that MRI seems to detect most of BRCA2-associated breast 
cancers.
It should be noted that 2 of 4 interval cancers and 3 of 8 
mammography-only cancers were in retrospect visible at the 
MRI scan, though not recalled. While unfortunate, this finding 
is not unexpected, and in line with previous studies that retro-
spectively evaluated MRI scans of patients with breast cancer 
initially reported to be negative [32–34]. The missed lesions 
and the higher number of mammography-only lesions in this 
patient population explain the relatively low MRI sensitivity.
The main limitation of our study is its retrospective design. 
However, to avoid information bias, the original allocated BI-
RADS classifications were used. Moreover, we included data 
from consecutive patient series when possible. Furthermore, 
although we present a large cohort of BRCA2 breast cancer 
cases, the sample size is still small. In addition, no informa-
tion can be provided about the specificity of the screening 
modalities as we evaluated only breast cancers cases and not a 
complete screened cohort. However, Vreemann et al. reported 
a specificity of 84.8% for first-round MRI examinations in 
BRCA2 carriers, which steeply increases to 97.4% in follow-
up rounds, but is still somewhat lower than for mammogra-
phy (94.4% and 98.8%, respectively) [35]. Likewise Bick et al. 
reported, for BRCA2 mutation carriers, a specificity of 85.1% 
in first-round examinations and 92.9% in follow-up examina-
tions using multimodality screening [36]. Further large pro-
spective screening cohorts studies, like the High Risk Ontario 
Breast Screening Program, are necessary to define the optimal 
screening protocol for BRCA1 and BRCA2 mutation carriers.
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Conclusions
Mammographic screening appears to have minimal benefit 
over MRI screening in BRCA2 mutation carriers younger 
than 40 years and may not overcome the disadvantages of 
increased radiation risks.
In BRCA2 mutation carriers of 50 years and older, mam-
mographic screening contributed significantly in the detec-
tion of early-stage breast cancer. We propose to omit mam-
mographic screening in young BRCA2 mutation carriers and 
suggest to postpone mammographic screening in BRCA2 
mutation carriers to at least age 40, or even to age 50. While 
the mammography-only lesions were predominantly DCIS 
one could also consider to perform mammographic screen-
ing every two years, starting at age 40.
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